Moneycontrol PRO
you are here: HomeNewsBusiness

Granules India gets Health Canada nod to market arthritis tablets

The company has received approval from Health Canada for Acetaminophen extended-release tablets OTC, 650 mg, Granules India said in a regulatory filing.

August 30, 2021 / 01:49 PM IST
Wockhardt | Promoter Themisto Trustee Company pledged 22.27 lakh shares of the company. With this, the percent of pledged shares now increased to 26.92 percent.

Wockhardt | Promoter Themisto Trustee Company pledged 22.27 lakh shares of the company. With this, the percent of pledged shares now increased to 26.92 percent.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Granules India on Monday said it has received marketing nod from Health Canada for its Acetaminophen extended-release tablets used in the treatment of arthritis pain.

The company has received approval from Health Canada for Acetaminophen extended-release tablets OTC, 650 mg, Granules India said in a regulatory filing.

"We received the approval within eight months of filing. This is a step towards global expansion of our core molecules. The approval of Acetaminophen extended-release tablets OTC, 650mg..., is a good addition to our portfolio," Granules USA, Inc & Granules Pharmaceuticals, Inc Executive Director Priyanka Chigurupati said.

The company will be launching the product in Canadian market soon, she added.

The drug will be manufactured at the company''s manufacturing facility located in Gagillapur, Hyderabad, the filing said.

Close
Shares of Granules India Ltd were trading at Rs 335.90 per scrip on BSE, up 1.53 percent from its previous close.
PTI
first published: Aug 30, 2021 01:51 pm
Sections
ISO 27001 - BSI Assurance Mark